Track Clearside Biomedical, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Clearside Biomedical, Inc. CLSD · Stock Open Clearside Biomedical, Inc. in new tab

0.4100 USD
EPS
-5.11
P/B
-0.04
Beta
1.79
Target Price
60.00 USD
Loading chart...
Key Metrics
Earnings dateMay 12, 2026
EPS-5.11
Book Value-10.31
Price to Book-0.04
% Insiders12.884%
Growth
Revenue Growth-0.81%
Estimates
Forward P/E-0.08
Forward EPS-0.50
Target Mean Price60.00

DCF valuation

Model fair value for Clearside Biomedical, Inc. (CLSD)
Result
Sign in to run the valuation for CLSD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 60.00 USD (low 30.00, high 90.00)
Low 30.00
Mean 60.00
High 90.00
Price 0.4100
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Clearside Biomedical, Inc. Logo Clearside Biomedical, Inc. Analysis (CLSD)

United States Health Care Official Website Stock

Is Clearside Biomedical, Inc. a good investment? Clearside Biomedical, Inc. (CLSD) is currently trading at 0.4100 USD. Market analysts have a consensus price target of 60.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Clearside Biomedical, Inc. is expected to release its next earnings report on May 12, 2026. The market consensus estimate for Forward EPS is -0.50.

Investor FAQ

Does Clearside Biomedical, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Clearside Biomedical, Inc.?

Clearside Biomedical, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 12, 2026. The company currently has a trailing EPS of -5.11.

Company Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Exchange Ticker
NMS (United States) CLSD
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 15, 2025 0.07
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion